The Tuberculosis Drug Accelerator at year 10: what have we learned?

Lgenia’s Chief Executive Officer and Chief Scientific Officer, Dr. Philip Hipskind, recently multi-authored the paper “The Tuberculosis Drug Accelerator at year 10: what have we learned?” in the journal Nature Medicine.

The Tuberculosis Drug Accelerator, an experiment designed to facilitate collaboration in tuberculosis drug discovery by breaking down barriers among competing labs and institutions, has reached a 10-year landmark.

The paper reviews the consortium’s achievements, advantages, and limitations and advocates for the application of similar models to other diseases.

Learn more here: https://rdcu.be/cnL7S